ConductScience.org, home

Comparison · NCT03806452-e340830c

Hydroxycarbamide vs Placebo: Proportion of Patients With a Shift From Macroalbuminuria to Normoalbuminuria

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Hydroxycarbamide vs Placebo: Proportion of Patients With a Shift From Macroalbuminuria to Normoalbuminuria. Trial comparisons, record NCT03806452-e340830c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03806452-e340830c

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02330.004120.121wilson
Risk in group 2000.0918wilson
Risk difference, group 1 minus group 20.0233-0.07050.121newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on Hydroxycarbamide than on Placebo43from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Hydroxycarbamide
Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial.~Hydroxycarbamide: Hydroxycarbamide tablets of 100 and 1000 mg
143OG000
Group 2Placebo
Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial.~Placebo Oral Tablet: Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
038OG001

Outcome

Type
SECONDARY
Title
Proportion of Patients With a Shift From Macroalbuminuria to Normoalbuminuria
Description
Time frame
6 months
Population

Source ClinicalTrials.gov

Trial

Title
SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
NCT number
NCT03806452
Phases
PHASE2
Conditions
Sickle Cell Disease
Interventions
Hydroxycarbamide, Placebo Oral Tablet
Lead sponsor
Theravia
Results first posted
2025-05-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03806452-e340830c